Karo Pharma AB Stock
Price
Target price
-
-
-
-
-
?28.46
WKN: A14YW4 / Symbol: KARO / Name: Karo Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Karo Pharma AB Stock
Karo Pharma AB is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
Based on the current price of 5.44 € the target price of 28 € shows a potential of 414.71% for Karo Pharma AB which would more than double the current price.
Pros and Cons of Karo Pharma AB in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karo Pharma AB vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karo Pharma AB | - | - | - | - | - | - | - |
| Medivir AB | 6.640% | 7.143% | 2.319% | -64.734% | 2.834% | -71.945% | -86.827% |
| Active Biotech AB | 2.450% | -4.810% | -0.265% | -38.961% | 25.753% | -71.298% | -86.807% |
| NanoViricides Inc. | -0.980% | -7.339% | 0.000% | -15.833% | 6.878% | -70.893% | -78.015% |
Comments
Karooooo Ltd. (NASDAQ: KARO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
Show more
Ratings data for KARO provided by MarketBeat
Karooooo Ltd. (NASDAQ: KARO) had its price target lowered by analysts at Morgan Stanley from $34.00 to $31.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for KARO provided by MarketBeat
Karooooo Ltd. (NASDAQ: KARO) had its price target raised by analysts at Raymond James from $26.00 to $29.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KARO provided by MarketBeat
